Potential of Newcastle disease virus in the fight against cancer in animals
Keywords:
NDV, animal cancer, oncolytic virotherapy.
Abstract
This review article describes the use of Newcastle disease virus (NDV) as an oncolytic agent, relevant biological characteristics of various oncolytic strains, the mechanisms of oncolysis, their immunological activities and various safety aspects are considered in the use of NDV in virotherapy oncolytic (VTO) against cancer in humans and animals. The use of this virus in clinical studies of VTO in domestic and wild animals is strongly suggested, as it is a cheap, safe and highly effective option for the treatment of neoplasms.
References
REFERÊNCIAS BIBLIOGRÁFICAS
1- Boddy AM et al. Comparative oncology: new insights into an ancient disease. iScience, 23, 101373, 2020. https://www.cell.com/action/showPdf?pii=S2589-0042%2820%2930561-7.
2- Hamede R et al. The ecology and evolution of wildlife cancers: applications for management and conservation. Evolutionary Applications, 13:1719–1732, 2020. https://onlinelibrary.wiley.com/doi/epdf/10.1111/eva.12948.
3- Lam HY et al. Safety and clinical usage of Newcastle disease virus in cancer therapy. Journal of Biomedicine and Biotechnology, v. 2011. https://www.hindawi.com/journals/bmri/2011/718710/.
4- Oh JH et al. Comparative oncology: overcoming human cancer through companion animal studies. Experimental & Molecular Medicine, 55:725 – 734, 2023. https://www.nature.com/articles/s12276-023-00977-3.
5- Cekanova M et al. Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Design, Development and Therapy, 8: 1911–1922, 2014. https://www.dovepress.com/getfile.php?fileID=22022.
6- Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review). International Journal of Oncology, 54: 407-419, 2018. https://www.spandidos-publications.com/10.3892/ijo.2018.4661.
7- Meng Q et al. Advances in the study of antitumour immunotherapy for Newcastle Disease Virus. International Journal of Medical Sciences, 18(11): 2294-2302, 2021. https://www.medsci.org/v18p2294.htm.
8- Patil SS et al. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. Journal of Translational Medicine, 10:3, 2012. https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-3.
9- Gentschev I et al. Oncolytic virotherapy of canine and feline cancer. Viruses, 6, 2122-2137, 2014. https://www.mdpi.com/1999-4915/6/5/2122.
10- Macneill AL. On the potential of oncolytic virotherapy for the treatment of canine cancers. Oncolytic Virotherapy, 4:95–107, 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918385/.
11- Bilgiç B et al. Oncolytic virotherapy and the current approaches in veterinary medicine. German Journal of Veterinary Research, 2(2):17-27, 2022. https://gmpc-akademie.de/articles/gjvr/single/68.
12- Kwon JY et al. Canine as a comparative and translational model for human mammary tumor. Journal Breast Cancer, 26(1):1-13, 2023. https://ejbc.kr/DOIx.php?id=10.4048/jbc.2023.26.e4.
13- Sánchez D et al. Oncolytic viruses for canine cancer treatment. Cancers, 10, 404, 2018. https://www.mdpi.com/2072-6694/10/11/404.
14- Melcher A et al. Oncolytic virotherapy as immunotherapy. Science, 374, 1325-1326, 2021. https://www.science.org/doi/10.1126/science.abk3436.
15- Rodrigues L et al. Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics. Nature Scientifc Reports, 13:10935, 2023. https://www.nature.com/articles/s41598-023-37505-2.
16- Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews, 8, 147-156, 2008. https://www.nature.com/articles/nrc2273.
17- Lin D et al. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduction and Targeted Therapy, 8:156, 2023. https://www.nature.com/articles/s41392-023-01407-6.
18- Russell L et al. Oncolytic viruses: priming time for cancer immunotherapy. BioDrugs 33:485–501, 2019. https://link.springer.com/article/10.1007/s40259-019-00367-0.
19- Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiology, 7(3): 347–367, 2012. https://www.futuremedicine.com/doi/10.2217/fmb.12.4.
20- Burman B et al. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers, 12, 3552, 2020. https://www.mdpi.com/2072-6694/12/12/3552.
21- Schirrmacher V. Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic Newcastle disease virus. Biomedicines, 10, 562, 2022. https://www.mdpi.com/2227-9059/10/3/562.
22- Ross CS et al. JMM Profile: Avian paramyxovirus type-1 and Newcastle disease: a highly infectious vaccine-preventable viral disease of poultry with low zoonotic potential. Journal of Medical Microbiology, 71:001489, 2022. https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.001489.
23- Sánchez D et al. Newcastle disease virus: potential therapeutic application for human and canine lymphoma. Viruses, 8:3 2016. https://www.mdpi.com/1999-4915/8/1/3.
24- Santos MR et al. Oncolytic effect of Newcastle disease virus is attributed to interferon regulation in canine mammary cancer cell lines. Veterinary and Comparative Oncology, 19:593–601, 2021. https://onlinelibrary.wiley.com/doi/10.1111/vco.12699.
25- Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. Journal of Clinical Virology, 16, 1–15, 2000. https://www.sciencedirect.com/science/article/abs/pii/S1386653299000724?via%3Dihub.
26- Chen L et al. Oncolytic activity of wild-type Newcastle disease virus HK84 against hepatocellular carcinoma associated with activation of type I interferon signaling. Journal of Clinical and Translational Hepatology, 10(2):284–296, 2022. https://www.xiahepublishing.com/2310-8819/JCTH-2021-00284.
27- Ch’ng WC et al. The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-b signaling. Journal of Interferon & Cytokine Research, 33(7), 2013. https://www.liebertpub.com/doi/10.1089/jir.2012.0095.
28- Jiang K et al. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. BMC Cancer, 18:746, 2018. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4522-3.
29- Yurchenko KS et al. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. PLoS ONE, 13(4), e0195425, 2018. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0195425.
30- Assayaghi RM et al. Apoptosis induction of Newcastle disease virus strains (AF 2240 & V4-UPM) on HT-29 human colorectal adenocarcinoma cells. Journal of Cancer Research and Therapeutic Oncology, 4:101, 2016. https://www.jscholaronline.org/full-text/JCRTO/5_101/Apoptosis-Induction-of-Newcastle-Disease-Virus-Strains.php.
31- Yurchenko KS et al. Adaptation of the Newcastle disease virus to cell cultures for enhancing its oncolytic properties. Acta Naturae, 11(40), 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475870/.
32- Khansari N, Bonab SF. Virotherapy with Newcastle disease virus for cancer treatment and its efficacy in clinical trials. Journal of Immunology Research, 5(6):119‒122, 2017. https://medcraveonline.com/MOJI/MOJI-05-00176.pdf.
33- Plitt T, Zamarin D. Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. Journal of Clinical Investigation, 5(1), 75–87, 2015. https://www.openaccessjournals.com/articles/cancer-therapy-with-newcastle-disease-virus-rationale-for-new-immunotherapeutic-combinations.pdf.
34- Tayeb S et al. Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virotherapy, 4:2015. https://www.dovepress.com/therapeutic-potential-of-oncolytic-newcastle-disease-virus-a-critical--peer-reviewed-fulltext-article-OV.
35- Fiola C et al. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. International Journal of Cancer, 119, 328–338, 2006. https://onlinelibrary.wiley.com/doi/10.1002/ijc.21821.
36- Rivera OAO et al. Inhibition of tumor growth and metastasis by Newcastle disease virus strain P05 in a breast cancer mouse model. Journal Breast Cancer, 26(2):186-200, 2023. https://ejbc.kr/DOIx.php?id=10.4048/jbc.2023.26.e9.
37- Ye T et al. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. American Journal Cancer Research, 8(8):1514-1527, 2018. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129498/.
38- Cuoco JA et al. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma. Neurosurgical Focus, v. 50, 2021. https://thejns.org/focus/view/journals/neurosurg-focus/50/2/article-pE8.xml.
39- Burke S et al. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Cancer Immunology, Immunotherapy, 69:1015–1027, 2020. https://link.springer.com/article/10.1007/s00262-020-02495-x.
40- Ivanković S et al. Oncolytic activity of Newcastle disease virus strain ZG1999HDS on oral malignant melanoma in dog: a case report. Veterinaria, 71(2), 243-254, 2022. https://journal.veterinaria-sarajevo.com/vfs/index.php/journal/article/view/380.
41- Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer v. 18, 1965. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142(196507)18:7%3C863::AID-CNCR2820180714%3E3.0.CO;2-V.
42- Pathak U et al. The viral knock: ameliorating cancer treatment with oncolytic Newcastle disease virus. Life,13,1626, 2023. https://doi.org/10.3390/ life13081626. https://www.mdpi.com/2075-1729/13/8/1626.
43- Siswanto FM, Arunngam P. Combination of oncolytic Newcastle disease virus (Ndv) and vaccine vector adenovirus (Adv) as a potential virotherapy for cancer: a systematic review. Anatomy Physiology & Biochemistry International Journal, 4(5): 555649, 2018. https://juniperpublishers.com/apbij/pdf/APBIJ.MS.ID.555649.pdf.
44- Achard C et al. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. Life, 13, 1626, 2023. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(18)30148-8/fulltext.
45- Alkassar M et al. The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. Journal of Neuro-Oncology, 104(3):715–727, 2011. https://link.springer.com/article/10.1007/s11060-011-0606-5.
46- Mcausland TM et al. Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. Molecular Therapy: Oncolytics, 20, 2021.
47- Zhang Y et al. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell International, 21:262, 2021. https://cancerci.biomedcentral.com/articles/10.1186/s12935-021-01972-2.
48- Lovatt C, Parker AL. Oncolytic viruses and immune checkpoint inhibitors: the “hot” new power couple. Cancers, 15, 4178, 2023. https://www.mdpi.com/2072-6694/15/16/4178.
49- Vijayakumar G et al. Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines. Journal of Virology, 94:e01677-19. https://journals.asm.org/doi/10.1128/jvi.01677-19.
50- Schirrmacher V, Fournier P. Multimodal cancer therapy involving oncolytic Newcastle disease virus, autologous immune cells, and bi-specific. Frontiers in Oncology, 4, 224, 2014. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2014.00224/full.
51- Thomas RJ, Bartee E. The use of oncolytic virotherapy in the neoadjuvant setting. Journal for ImmunoTherapy of Cancer, 10:e004462. https://jitc.bmj.com/content/10/4/e004462.
52- Schirrmacher V. Fifty years of clinical application of Newcastle disease virus: time to celebrate! Biomedicines, 4:16, 2016. https://www.mdpi.com/2227-9059/4/3/16.
53- Queiroga F, Cogliati B. Translational and comparative research on innovative anti-cancer therapies. Cancers, 15, 1335, 2023. https://www.mdpi.com/2072-6694/15/4/1335.
54- Biller BJ. Cancer immunotherapy for the veterinary patient. Veterinary Clinics Small Animal, 37:1137–1149, 2007. https://www.sciencedirect.com/science/article/abs/pii/S0195561607000903?via%3Dihub.
1- Boddy AM et al. Comparative oncology: new insights into an ancient disease. iScience, 23, 101373, 2020. https://www.cell.com/action/showPdf?pii=S2589-0042%2820%2930561-7.
2- Hamede R et al. The ecology and evolution of wildlife cancers: applications for management and conservation. Evolutionary Applications, 13:1719–1732, 2020. https://onlinelibrary.wiley.com/doi/epdf/10.1111/eva.12948.
3- Lam HY et al. Safety and clinical usage of Newcastle disease virus in cancer therapy. Journal of Biomedicine and Biotechnology, v. 2011. https://www.hindawi.com/journals/bmri/2011/718710/.
4- Oh JH et al. Comparative oncology: overcoming human cancer through companion animal studies. Experimental & Molecular Medicine, 55:725 – 734, 2023. https://www.nature.com/articles/s12276-023-00977-3.
5- Cekanova M et al. Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Design, Development and Therapy, 8: 1911–1922, 2014. https://www.dovepress.com/getfile.php?fileID=22022.
6- Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review). International Journal of Oncology, 54: 407-419, 2018. https://www.spandidos-publications.com/10.3892/ijo.2018.4661.
7- Meng Q et al. Advances in the study of antitumour immunotherapy for Newcastle Disease Virus. International Journal of Medical Sciences, 18(11): 2294-2302, 2021. https://www.medsci.org/v18p2294.htm.
8- Patil SS et al. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. Journal of Translational Medicine, 10:3, 2012. https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-3.
9- Gentschev I et al. Oncolytic virotherapy of canine and feline cancer. Viruses, 6, 2122-2137, 2014. https://www.mdpi.com/1999-4915/6/5/2122.
10- Macneill AL. On the potential of oncolytic virotherapy for the treatment of canine cancers. Oncolytic Virotherapy, 4:95–107, 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918385/.
11- Bilgiç B et al. Oncolytic virotherapy and the current approaches in veterinary medicine. German Journal of Veterinary Research, 2(2):17-27, 2022. https://gmpc-akademie.de/articles/gjvr/single/68.
12- Kwon JY et al. Canine as a comparative and translational model for human mammary tumor. Journal Breast Cancer, 26(1):1-13, 2023. https://ejbc.kr/DOIx.php?id=10.4048/jbc.2023.26.e4.
13- Sánchez D et al. Oncolytic viruses for canine cancer treatment. Cancers, 10, 404, 2018. https://www.mdpi.com/2072-6694/10/11/404.
14- Melcher A et al. Oncolytic virotherapy as immunotherapy. Science, 374, 1325-1326, 2021. https://www.science.org/doi/10.1126/science.abk3436.
15- Rodrigues L et al. Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics. Nature Scientifc Reports, 13:10935, 2023. https://www.nature.com/articles/s41598-023-37505-2.
16- Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews, 8, 147-156, 2008. https://www.nature.com/articles/nrc2273.
17- Lin D et al. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduction and Targeted Therapy, 8:156, 2023. https://www.nature.com/articles/s41392-023-01407-6.
18- Russell L et al. Oncolytic viruses: priming time for cancer immunotherapy. BioDrugs 33:485–501, 2019. https://link.springer.com/article/10.1007/s40259-019-00367-0.
19- Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiology, 7(3): 347–367, 2012. https://www.futuremedicine.com/doi/10.2217/fmb.12.4.
20- Burman B et al. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers, 12, 3552, 2020. https://www.mdpi.com/2072-6694/12/12/3552.
21- Schirrmacher V. Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic Newcastle disease virus. Biomedicines, 10, 562, 2022. https://www.mdpi.com/2227-9059/10/3/562.
22- Ross CS et al. JMM Profile: Avian paramyxovirus type-1 and Newcastle disease: a highly infectious vaccine-preventable viral disease of poultry with low zoonotic potential. Journal of Medical Microbiology, 71:001489, 2022. https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.001489.
23- Sánchez D et al. Newcastle disease virus: potential therapeutic application for human and canine lymphoma. Viruses, 8:3 2016. https://www.mdpi.com/1999-4915/8/1/3.
24- Santos MR et al. Oncolytic effect of Newcastle disease virus is attributed to interferon regulation in canine mammary cancer cell lines. Veterinary and Comparative Oncology, 19:593–601, 2021. https://onlinelibrary.wiley.com/doi/10.1111/vco.12699.
25- Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. Journal of Clinical Virology, 16, 1–15, 2000. https://www.sciencedirect.com/science/article/abs/pii/S1386653299000724?via%3Dihub.
26- Chen L et al. Oncolytic activity of wild-type Newcastle disease virus HK84 against hepatocellular carcinoma associated with activation of type I interferon signaling. Journal of Clinical and Translational Hepatology, 10(2):284–296, 2022. https://www.xiahepublishing.com/2310-8819/JCTH-2021-00284.
27- Ch’ng WC et al. The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-b signaling. Journal of Interferon & Cytokine Research, 33(7), 2013. https://www.liebertpub.com/doi/10.1089/jir.2012.0095.
28- Jiang K et al. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. BMC Cancer, 18:746, 2018. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4522-3.
29- Yurchenko KS et al. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. PLoS ONE, 13(4), e0195425, 2018. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0195425.
30- Assayaghi RM et al. Apoptosis induction of Newcastle disease virus strains (AF 2240 & V4-UPM) on HT-29 human colorectal adenocarcinoma cells. Journal of Cancer Research and Therapeutic Oncology, 4:101, 2016. https://www.jscholaronline.org/full-text/JCRTO/5_101/Apoptosis-Induction-of-Newcastle-Disease-Virus-Strains.php.
31- Yurchenko KS et al. Adaptation of the Newcastle disease virus to cell cultures for enhancing its oncolytic properties. Acta Naturae, 11(40), 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475870/.
32- Khansari N, Bonab SF. Virotherapy with Newcastle disease virus for cancer treatment and its efficacy in clinical trials. Journal of Immunology Research, 5(6):119‒122, 2017. https://medcraveonline.com/MOJI/MOJI-05-00176.pdf.
33- Plitt T, Zamarin D. Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. Journal of Clinical Investigation, 5(1), 75–87, 2015. https://www.openaccessjournals.com/articles/cancer-therapy-with-newcastle-disease-virus-rationale-for-new-immunotherapeutic-combinations.pdf.
34- Tayeb S et al. Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virotherapy, 4:2015. https://www.dovepress.com/therapeutic-potential-of-oncolytic-newcastle-disease-virus-a-critical--peer-reviewed-fulltext-article-OV.
35- Fiola C et al. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. International Journal of Cancer, 119, 328–338, 2006. https://onlinelibrary.wiley.com/doi/10.1002/ijc.21821.
36- Rivera OAO et al. Inhibition of tumor growth and metastasis by Newcastle disease virus strain P05 in a breast cancer mouse model. Journal Breast Cancer, 26(2):186-200, 2023. https://ejbc.kr/DOIx.php?id=10.4048/jbc.2023.26.e9.
37- Ye T et al. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. American Journal Cancer Research, 8(8):1514-1527, 2018. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129498/.
38- Cuoco JA et al. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma. Neurosurgical Focus, v. 50, 2021. https://thejns.org/focus/view/journals/neurosurg-focus/50/2/article-pE8.xml.
39- Burke S et al. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Cancer Immunology, Immunotherapy, 69:1015–1027, 2020. https://link.springer.com/article/10.1007/s00262-020-02495-x.
40- Ivanković S et al. Oncolytic activity of Newcastle disease virus strain ZG1999HDS on oral malignant melanoma in dog: a case report. Veterinaria, 71(2), 243-254, 2022. https://journal.veterinaria-sarajevo.com/vfs/index.php/journal/article/view/380.
41- Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer v. 18, 1965. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142(196507)18:7%3C863::AID-CNCR2820180714%3E3.0.CO;2-V.
42- Pathak U et al. The viral knock: ameliorating cancer treatment with oncolytic Newcastle disease virus. Life,13,1626, 2023. https://doi.org/10.3390/ life13081626. https://www.mdpi.com/2075-1729/13/8/1626.
43- Siswanto FM, Arunngam P. Combination of oncolytic Newcastle disease virus (Ndv) and vaccine vector adenovirus (Adv) as a potential virotherapy for cancer: a systematic review. Anatomy Physiology & Biochemistry International Journal, 4(5): 555649, 2018. https://juniperpublishers.com/apbij/pdf/APBIJ.MS.ID.555649.pdf.
44- Achard C et al. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. Life, 13, 1626, 2023. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(18)30148-8/fulltext.
45- Alkassar M et al. The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. Journal of Neuro-Oncology, 104(3):715–727, 2011. https://link.springer.com/article/10.1007/s11060-011-0606-5.
46- Mcausland TM et al. Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. Molecular Therapy: Oncolytics, 20, 2021.
47- Zhang Y et al. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell International, 21:262, 2021. https://cancerci.biomedcentral.com/articles/10.1186/s12935-021-01972-2.
48- Lovatt C, Parker AL. Oncolytic viruses and immune checkpoint inhibitors: the “hot” new power couple. Cancers, 15, 4178, 2023. https://www.mdpi.com/2072-6694/15/16/4178.
49- Vijayakumar G et al. Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines. Journal of Virology, 94:e01677-19. https://journals.asm.org/doi/10.1128/jvi.01677-19.
50- Schirrmacher V, Fournier P. Multimodal cancer therapy involving oncolytic Newcastle disease virus, autologous immune cells, and bi-specific. Frontiers in Oncology, 4, 224, 2014. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2014.00224/full.
51- Thomas RJ, Bartee E. The use of oncolytic virotherapy in the neoadjuvant setting. Journal for ImmunoTherapy of Cancer, 10:e004462. https://jitc.bmj.com/content/10/4/e004462.
52- Schirrmacher V. Fifty years of clinical application of Newcastle disease virus: time to celebrate! Biomedicines, 4:16, 2016. https://www.mdpi.com/2227-9059/4/3/16.
53- Queiroga F, Cogliati B. Translational and comparative research on innovative anti-cancer therapies. Cancers, 15, 1335, 2023. https://www.mdpi.com/2072-6694/15/4/1335.
54- Biller BJ. Cancer immunotherapy for the veterinary patient. Veterinary Clinics Small Animal, 37:1137–1149, 2007. https://www.sciencedirect.com/science/article/abs/pii/S0195561607000903?via%3Dihub.
Published
2023-12-20
Section
Saúde
Declaro que os conteúdos apresentados nos artigos e demais trabalhos são de minha autoria e tenho total responsabilidade sobre os mesmos, os quais estou cedendo os direitos autorais à Revista Saúde e Meio Ambiente, para fins de divulgação científica em qualquer meio disponível.
